StockData
Vor Biopharma Inc. logo

Vor Biopharma Inc. (VOR) stock

VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 5/30
$19.42+0.10 (+0.52%)

Close on Nov 13, 2026Market cap $1.19BP/E –Yield –

Earnings

Vor Biopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Vor Biopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Jan 12, 2026during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Vor Biopharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Vor Biopharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Vor Biopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise
    Update
  2. First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN)
    Update
  3. First regulatory approval for Sjögren’s disease (SjD)
    Update
  4. Vor Bio Announces $75 Million Private Placement with TCGX
    Update
  5. Quarterly results release
    Results
  6. Vor Bio Announces $150 Million Private Placement
    Update
  7. Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
    Update
  8. 8-K exhibit EX-99.1
    Update
  9. 8-K exhibit EX-99.1
    Update
  10. Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
    Update
  11. Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
    Update
  12. Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business
    Update
  13. Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
    Update
  14. Vor Bio Announces $175 Million Private Placement
    Update
  15. Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
    News

See a number that looks wrong?